GlobeNewswire Inc | Sep 28, 2021 04:30PM EDT

September 28, 2021

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in October.

Scientific conferences:

Event: AACR: Tumor Immunology and Immunotherapy ? Details GEN-011: A neoantigen-targeted peripheral blood-derived T cell therapyTopic: that has broad neoantigen specificity and high T cell purity while avoiding pro-tumor cellsFormat: Poster presentationDate: Tuesday-Wednesday, October 5-6^thTime: Available throughout the conference

Event: Meeting on the Mesa ? DetailsTopic: Next-generation neoantigen-targeted solid tumor T cell therapyFormat: PresentationDate: Tuesday-Thursday, October 12-14^thTime: Available throughout the conference

Event: CMO Summit ? DetailsTopic: Communicating and Pivoting After a Failed Clinical TrialFormat: PanelDate: Friday, October 15^thTime: 1:00 p.m. ET

Event: TIL Therapies Digital Summit ? DetailsTopic: Identification of Inhibigens^TM May be the Key to Successful T cell Therapies for Solid TumorsFormat: PresentationDate: Tuesday, October 19^thTime: 11:00 a.m. ET

Event: Neoantigen-Based Therapies Summit ? DetailsTopic Prioritizing Diversity, Equity, and Inclusion in the Neoantigen Field1: Roundtable discussion Tuesday, October 26^th 12:40 p.m. ETTopic Responses to Inhibitory Tumor Antigens, Inhibigens^TM, Suppresses2: Anti-Tumor Immunity & promote Tumor Growth Presentation Wednesday, October 27^th 12:30 p.m. ETTopic Unleashing the Titans: The GEN-011 Neoantigen-Targeted Peripheral T cell3: Therapy for Solid Tumors Presentation Wednesday, October 27^th 5:30 p.m. ET

About Genocea Biosciences, Inc.Genoceas mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS platform can comprehensively profile each patients T cell responses to potential targets, or antigens, on that patients tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens, that drive pro-tumor immune responses. We are conducting a Phase 1/2a clinical trial for GEN-011, our investigational adoptive T cell therapy comprising neoantigen-targeted peripheral cells. We continue to monitor patients in our phase 1/2a clinical trial for GEN-009, our investigational neoantigen vaccine. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com.

Forward-Looking StatementsThis press release includes forward-looking statements related to GEN-011, GEN-009 and research updates within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. These factors include, but are not limited to, risks related to the potential failure of our active product candidates which are in an early stage of clinical development; our ability to obtain regulatory approval for our current and future product candidates; potential delays in enrolling patients in our clinical trials; our reliance on third parties to conduct technical development, non-clinical studies and clinical trials for our product candidates; our reliance on third parties to conduct some or all aspects of our product manufacturing; our ability to obtain or protect intellectual property rights related to our product candidates; the potential impacts of COVID-19 on our business and financial results; changes in law, regulations, or interpretations and enforcement of regulatory guidance; our need for additional financing and the risks listed under Risk Factors in our annual report on Form 10-K for the year ended December 31, 2020 and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

Investor Contact: Media Contact:Dan Ferry Sarah O?Connell617-430-7576 soconnell@vergescientific.comdaniel@lifesciadvisors.com